{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T06:02:48Z","timestamp":1670652168357},"reference-count":23,"publisher":"ALUNA","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:p>The aim: To investigate the peculiarities of colon microbiocenosis disorders in patients with chronic hepatitis C. \nMaterials and methods: 142 patients with CHC were under observation, determination of the degree of liver fibrosis (FibroMax), bacteriological examination of stools and pancreatic elastase was performed. \nResults: It was found that 59.2% of patients with CHC had gut dysbiosis (DB), of which 61.9% had increased body weight. Intestinal microbiocenosis disorders were manifested by constipation in 57.1% of patients, diarrhea in 31% of patients, and alternating constipation and diarrhea in 11.9% of patients. Bacteriologically, gut dysbiosis was character\u00acized by suppression of the growth of normal microflora: Escherichia coli in 47.6%, bifidobacteria in 61.9%, lactobacilli in 53.6%, complete absence of bifidobacteria in 20.2% of cases. In patients with CHC combined with DB deep stages of liver fibrosis (F2-3 and F3-4) are registered 3.6 times more often compared to patients without intestinal dysbiosis (53.6% versus 24.1% and 11.9% versus 3.4%). The degree of gut DB increased in proportion to the stage of liver fibrosis (p&lt;0.05). 32.1% of patients with CHC with dysbiosis were diagnosed with exocrine insufficiency of the pancreas. \nConclusions: Gut dysbiosis occurs more often in CHC patients with increased body weight and is characterized by constipation in 59.2% of patients. Intestinal microbiocenosis is characterized by suppression of the growth of normal microflora. In 32.1% of CHC patients with intestinal dysbiosis, according to the results of the pancreatic elastase-1 test, pancreatic exocrine insufficiency of various degrees was found.<\/jats:p>","DOI":"10.36740\/wlek202210104","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T19:30:28Z","timestamp":1670614228000},"page":"2334-2338","source":"Crossref","is-referenced-by-count":0,"title":["ASSESSMENT OF COLON MICROBIOCENOSIS DISORDERS IN PATIENTS WITH CHRONIC HEPATITIS C"],"prefix":"10.36740","volume":"75","author":[{"given":"Mariya A.","family":"Derbak","sequence":"first","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vir\u0430 V.","family":"Vorobets","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina M.","family":"Koval","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olena \u0406.","family":"Nikolska","sequence":"additional","affiliation":[{"name":"SHUPYK NATIONAL HEALTHCARE UNIVERSITY OF UKRAINE, KYIV, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olena V.","family":"Ustych","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mykhaylo M.","family":"Hechko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andriy V.","family":"Ilko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2022]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013; 29(3):264-70. doi: 10.1097\/ MOG.0b013e32835ff948.","DOI":"10.1097\/MOG.0b013e32835ff948"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Wellh\u00f6ner F. et al. Eradication of chronic HCV infection: Improvement of dysbiosis only in patients without liver cirrhosis. Hepatology. 2021; 74: 72-82. doi: 10.1002\/hep.31700.","DOI":"10.1002\/hep.31700"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Albillos A., de Gottardi A., Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72(3):558-577. doi: 10.1016\/j.jhep.2019.10.003.","DOI":"10.1016\/j.jhep.2019.10.003"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Woodhouse C.A., Patel V.C., Singanayagam A., Shawcross D.L. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Alimentary Pharmacology & Therapeutics. 2018;47, 192-202. doi:10.1111\/apt.14397.","DOI":"10.1111\/apt.14397"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the man-agement of non-alcoholic fatty liver disease. Journal of Hepatology. 2016; 64: 1388-402. doi:10.1016\/j. jhep.2015.11.004.","DOI":"10.1007\/s00125-016-3902-y"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Ohtani N., Kawada N. Role of the gut-liver axis in liver inflammation, fibro-sis, and cancer: A special focus on the gut microbiota relationship. Hepatol. Commun. 2019;3: 456-470. doi:10.1002\/hep4.1331.","DOI":"10.1002\/hep4.1331"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7. Nahon P., Bourcier V., Layese R. et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152:142-156.","DOI":"10.1053\/j.gastro.2016.09.009"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Woodhouse C.A., Patel V.C., Singanayagam A., Shawcross D.L. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018;47(2):192-202. doi: 10.1111\/apt.14397.","DOI":"10.1111\/apt.14397"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. Bruno S., Di Marco V., Iavarone M. et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016;64:1217-1223.","DOI":"10.1016\/j.jhep.2016.01.034"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. D\u2019Mello C., Swain M.G. Immune-to-Brain Communication Pathways in Inflammation-Associated Sickness and Depression. Curr. Top. Behav. Neurosci. 2017; 31: 73-94. doi: 10.1007\/7854_2016_37.","DOI":"10.1007\/7854_2016_37"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Benten D., Wiest R. Gut microbiome and intestinal barrier failure \u2013 the \u201cAchilles heel\u201d in hepatology? J. Hepatol. 2012;56:1221-1223. doi: 10.1016\/j.jhep.2012.03.003.","DOI":"10.1016\/j.jhep.2012.03.003"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Schnabl B. Linking intestinal homeostasis and liver disease. Curr opin gastroenterol. 2014;29(3):264-70. doi: 10.1097\/ mog.0b013e32835ff948.","DOI":"10.1097\/MOG.0b013e32835ff948"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Roderburg C., Luedde T. The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. Gut Microbes. 2014;5 (5):441-5. doi: 10.4161\/gmic.29599.","DOI":"10.4161\/gmic.29599"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Rotar D.V., Sydorchuk L.I., Sydorchuk A.S. et al. Populjacijni zminu poroznunnoji microbiota tovstoi kusku chvoruch na chronichnuj virusnuj hepatut C [Population changes of colon lumen microbiota in patients with chronic hepatitis C]. Hastroenterolohiya. 2017;51:121-6. doi: 10.22141\/2308-2097.51.2.2017.101702.","DOI":"10.1016\/j.ijid.2018.04.4246"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Liu B.N., Liu X.T., Liang Z.H., Wang J.H. Gut microbiota in obesity.World J Gastroenterol. 2021; 27(25): 3837-3850. doi: 10.3748\/wjg.v27. i25.3837.","DOI":"10.3748\/wjg.v27.i25.3837"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Cuevas-Sierra A., Ramos-Lopez O., Riezu-Boj J.I. et al. Diet, Gut Microbiota, and Obesity: Links with Host Genetics and Epigenetics and Potential Applications. Adv Nutr. 2019;10(1):S17-S30. doi: 10.1093\/ advances\/nmy078.","DOI":"10.1093\/advances\/nmy078"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Zavhorodnia N. Yu., Lukianenko O. Yu., Klenina I. A. et al. Assessment of the intestinal microbiota and fecal short-chain fatty acids content in children with non-alcoholic fatty liver disease. Gastroenterology. 2020;54(1), 56-62. doi:10.22141\/2308-2097.54.1.2020.199143.","DOI":"10.14739\/2310-1210.2019.1.155816"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Wu D., Wang H., Xie L., Hu F. Cross-Talk Between Gut Microbiota and Adipose Tissues in Obesity and Related Metabolic Diseases. Front Endocrinol (Lausanne). 2022;13:908868. doi: 10.3389\/ fendo.2022.908868.","DOI":"10.3389\/fendo.2022.908868"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Negro F., Forton D., Crax\u00ec A. et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149(6) :1345-60; doi: 10.1053\/j.gastro.2015.08.035.","DOI":"10.1053\/j.gastro.2015.08.035"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Cacoub P., Comarmond C., Domont F. et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther. Adv. Infect. Dis. 2016; 3(1): 3-14; doi: 10.1177\/2049936115585942.","DOI":"10.1177\/2049936115585942"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21. Rosenthal E. Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus. 2015; 24(4-5): 469-82; doi: 10.1177\/0961203314556140.","DOI":"10.1177\/0961203314556140"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22. Babinets L.S., Shaygen O.R. Klinichni aspektu chronichnoho pankreatuty v pojednanni iz virusnum hepatutom C. [Clinical aspects of chronic pancreatitis in combination with viral hepatitis C] Zdobutku klinichnoi I eksperumentaljnoi meducunu. 2019; 2: 69-74. doi: 10.11603\/1811- 2471.2019.v0.i2.10371. (in Ukrainian).","DOI":"10.11603\/1811-2471.2019.v0.i2.10371"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Kumar K., Ghoshal U.C., Srivastava D. et al. Small intestinal bacterial overgrowth is common both among patients with alcoholic and idiopathic chronic pancreatitis. Pancreatology. 2014;14(4):280-3. doi: 10.1016\/j.pan.2014.05.792.","DOI":"10.1016\/j.pan.2014.05.792"}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T19:34:43Z","timestamp":1670614483000},"score":1,"resource":{"primary":{"URL":"https:\/\/wiadlek.pl\/wp-content\/uploads\/archive\/2022\/10\/WLek202210104.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022]]},"published-print":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202210104","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"value":"0043-5147","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}